<DOC>
	<DOCNO>NCT03014219</DOCNO>
	<brief_summary>The investigator propose study safety autologous mesenchymal stromal cell transfer use biomatrix ( Gore Bio-A Fistula Plug ) Phase I study use single dose 20 million cell . 20 patient ( age 12 17 year ) Crohns perianal fistula enrol . Subjects undergo standard adjuvant therapy include drainage infection placement drain seton . Six week post placement drain seton , seton replace MSC load Gore fistula plug per current clinical practice . The subject subsequently follow fistula response closure 24 month . This autologous product derive patient use patient .</brief_summary>
	<brief_title>Phase 1 Crohn 's Pediatric Sub-study MSC AFP</brief_title>
	<detailed_description>Visit 1 : Patients evaluate eligibility ( inclusion/exclusion checklist ) write , informed consent obtain . Patients undergo general exam vital sign . Patients schedule fat biopsy collect tissue need grow MSC . In event cell growth tissue obtain first biopsy , one attempt make second tissue sample patient . However , second attempt fail grow cell , attempt make , subject continue study . The subject subsequently follow fistula response closure 24 month . Study visit Day 1 , Week 2 , Week 4 , Week 8 , Week 12 , Week 24 , Week 52 , Week 104 . This autologous product derive patient use patient .</detailed_description>
	<mesh_term>Fistula</mesh_term>
	<criteria>Inclusion Criteria 1 . Males females 1217 year age . 2 . Residents United States . 3 . Crohn 's disease single multiple drain complex perianal fistula ( definition ) least three month despite standard therapy ( definition ) . 4 . Concurrent therapy corticosteroid , 5ASA drug , thiopurines , MTX , antibiotic , antiTNF therapy permit . 5 . All patient undergo colonoscopy last 12 month rule malignant premalignant condition 6 . Have contraindication MR evaluation : e.g . pacemaker magnetically active metal fragment , claustrophobia 7 . Ability comply protocol 8 . Competent able provide write informed consent ( assent appropriate ) . 9 . Must fail standard medical therapy include antiTNF agent Exclusion Criteria 1 . Inability obtain informed consent ( assent appropriate ) . 2 . Clinically significant medical condition within six month administration MSCs : e.g . sepsis , pneumonia active serious infection condition would , opinion investigator , compromise safety patient . 3 . Specific exclusion ; . Evidence hepatitis B , C , HIV 4 . History cancer include melanoma ( exception localize skin cancer ) 5 . Investigational drug within thirty ( 30 ) day baseline 6 . A resident outside United States 7 . Pregnant try become pregnant , breast feeding . 8 . History clinically significant autoimmunity ( Crohn 's disease ) previous example fatdirected autoimmunity 9 . Previous allergic reaction perianal fistula plug . 10 . If adipose tissue technically feasible 11 . Weight le 35 kg 12 . Allergic local anesthetic 13 . Nonenterocutaneous tract ( i.e . rectovaginal , enterovesicular )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>